|
1
|
Inokawa Y, Inaoka K, Sonohara F, Hayashi
M, Kanda M and Nomoto S: Molecular alterations in the
carcinogenesis and progression of hepatocellular carcinoma: Tumor
factors and background liver factors. Oncol Lett. 12:3662–3668.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fernández-Rodríguez CM and
Gutiérrez-García ML: Prevention of hepatocellular carcinoma in
patients with chronic hepatitis B. World J Gastrointest Pharmacol
Ther. 5:175–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li W, Man W, Guo H and Yang P: Clinical
study of transcatheter arterial chemoembolization combined with
microwave ablation in the treatment of advanced hepatocellular
carcinoma. J Cancer Res Ther. 12 Supplement:C217–C220. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buendia MA and Neuveut C: Hepatocellular
carcinoma. Cold Spring Harb Perspect Med. 5:a0214442015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang P, Zou F, Zhang X, Li H, Dulak A,
Tomko RJ Jr, Lazo JS, Wang Z, Zhang L and Yu J: microRNA-21
negatively regulates Cdc25A and cell cycle progression in colon
cancer cells. Cancer Res. 69:8157–8165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bulkowska M, Rybicka A, Senses KM, Ulewicz
K, Witt K, Szymanska J, Taciak B, Klopfleisch R, Hellmén E, Dolka
I, et al: MicroRNA expression patterns in canine mammary cancer
show significant differences between metastatic and non-metastatic
tumours. BMC Cancer. 17:7282017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu Z, Lin X, Tian M and Chang W: microRNA
196b promotes cell migration and invasion by targeting FOXP2 in
hepatocellular carcinoma. Oncol Rep. 39:731–738. 2018.PubMed/NCBI
|
|
10
|
Xue H and Tian GY: MiR-429 regulates the
metastasis and EMT of HCC cells through targeting RAB23. Arch
Biochem Biophys. 637:48–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qin A, Zhu J, Liu X, Zeng D, Gu M and Lv
C: MicroRNA-1271 inhibits cellular proliferation of hepatocellular
carcinoma. Oncol Lett. 14:6783–6788. 2017.PubMed/NCBI
|
|
12
|
Zhang D, Liu E, Kang J, Yang X and Liu H:
MiR-3613-3p affects cell proliferation and cell cycle in
hepatocellular carcinoma. Oncotarget. 8:93014–93028.
2017.PubMed/NCBI
|
|
13
|
Yu S, Qin X, Chen T, Zhou L, Xu X and Feng
J: MicroRNA-106b-5p regulates cisplatin chemosensitivity by
targeting polycystic kidney disease-2 in non-small-cell lung
cancer. Anticancer Drugs. 28:852–860. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arias Sosa LA, Cuspoca Orduz AF and Bernal
Gómez BM: Deregulation of microRNAs in gastric cancer: Up
regulation by miR-21 and miR-106. Rev Gastroenterol Peru. 37:65–70.
2017.(In Spanish). PubMed/NCBI
|
|
15
|
He QY, Wang GC, Zhang H, Tong DK, Ding C,
Liu K, Ji F, Zhu X and Yang S: miR-106a-5p suppresses the
proliferation, migration, and invasion of osteosarcoma cells by
targeting HMGA2. DNA Cell Biol. 35:506–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang GJ, Li JS, Zhou H, Xiao HX, Li Y and
Zhou T: MicroRNA-106b promotes colorectal cancer cell migration and
invasion by directly targeting DLC1. J Exp Clin Cancer Res.
34:732015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piao J, You K, Guo Y, Zhang Y, Li Z and
Geng L: Substrate stiffness affects epithelial-mesenchymal
transition of cervical cancer cells through miR-106b and its target
protein DAB2. Int J Oncol. 50:2033–2042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samal J, Kandpal M and Vivekanandan P:
HBeAg-induced miR-106b promotes cell growth by targeting the
retinoblastoma gene. Sci Rep. 7:143712017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu C, Shi L, Chen W, Fang P, Li J, Jin L,
Pan Z and Pan C: MiR-106b inhibitors sensitize TRAIL-induced
apoptosis in hepatocellular carcinoma through increase of death
receptor 4. Oncotarget. 8:41921–41931. 2017.PubMed/NCBI
|
|
20
|
Albertsen HM, Smith SA, Melis R, Williams
B, Holik P, Stevens J and White R: Sequence, genomic structure, and
chromosomal assignment of human DOC-2. Genomics. 33:207–213. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mok SC, Chan WY, Wong KK, Cheung KK, Lau
CC, Ng SW, Baldini A, Colitti CV, Rock CO and Berkowitz RS: DOC-2,
a candidate tumor suppressor gene in human epithelial ovarian
cancer. Oncogene. 16:2381–2387. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu S, Zhu J and Wu Z: Loss of Dab2
expression in breast cancer cells impairs their ability to deplete
TGF-β and induce Tregs development via TGF-β. PLoS One.
9:e917092014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Y, Zhang Y, Jiang L, Zhang M, Chen Z,
Liu D and Huang Q: Disabled homolog 2 is required for migration and
invasion of prostate cancer cells. Front Med. 9:312–321. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li C, Chen J, Chen T, Xu Z, Xu C, Ding C,
Wang Y, Lei Z, Zhang HT and Zhao J: Aberrant Hypermethylation at
Sites −86 to 226 of DAB2 Gene in Non-Small Cell Lung Cancer. Am J
Med Sci. 349:425–431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu YF, Mao YP, Li YQ, Ren XY, He QM, Tang
XR, Sun Y, Liu N and Ma J: MicroRNA-93 promotes cell growth and
invasion in nasopharyngeal carcinoma by targeting disabled
homolog-2. Cancer Lett. 363:146–155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li C, Ding C, Chen T, Chen J, Xu Z, Lei Z,
Xu C and Zhao J: Micro ribonucleic acid-93 promotes proliferation
and migration of esophageal squamous cell carcinoma by targeting
disabled 2. Thorac Cancer. 6:524–533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Calvisi DF, Ladu S, Gorden A, Farina M,
Lee JS, Conner EA, Schroeder I, Factor VM and Thorgeirsson SS:
Mechanistic and prognostic significance of aberrant methylation in
the molecular pathogenesis of human hepatocellular carcinoma. J
Clin Invest. 117:2713–2722. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Li N, Li X, Zhao W, Qiao Y, Liang
L and Ding Y: Low expression of DAB2IP contributes to malignant
development and poor prognosis in hepatocellular carcinoma. J
Gastroenterol Hepatol. 27:1117–1125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie BH, He X, Hua RX, Zhang B, Tan GS,
Xiong SQ, Liu LS, Chen W, Yang JY, Wang XN, et al: Mir-765 promotes
cell proliferation by downregulating INPP4B expression in human
hepatocellular carcinoma. Cancer Biomark. 16:405–413. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan J, Ji H, Xiao F, Lin Z, Zhao X, Wang
Z, Zhao J and Lu J: MicroRNA-340 inhibits the proliferation and
invasion of hepatocellular carcinoma cells by targeting JAK1.
Biochem Biophys Res Commun. 483:578–584. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Calvisi DF, Pinna F, Pellegrino R, Sanna
V, Sini M, Daino L, Simile MM, De Miglio MR, Frau M, Tomasi ML, et
al: Ras-driven proliferation and apoptosis signaling during rat
liver carcinogenesis is under genetic control. Int J Cancer.
123:2057–2064. 2008. View Article : Google Scholar : PubMed/NCBI
|
